Alumis Inc. (NASDAQ:ALMS) Given Consensus Recommendation of “Buy” by Analysts

Shares of Alumis Inc. (NASDAQ:ALMS) have been assigned a consensus rating of “Buy” from the nine ratings firms that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $26.57.

Several analysts have recently issued reports on ALMS shares. HC Wainwright decreased their price target on Alumis from $26.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Oppenheimer began coverage on shares of Alumis in a research report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price target on the stock. Robert W. Baird assumed coverage on shares of Alumis in a report on Thursday, October 31st. They set an “outperform” rating and a $25.00 price objective for the company. Finally, Baird R W upgraded shares of Alumis to a “strong-buy” rating in a research note on Thursday, October 31st.

Institutional Trading of Alumis

A number of institutional investors have recently modified their holdings of ALMS. BNP Paribas Financial Markets bought a new position in Alumis in the third quarter valued at about $27,000. MetLife Investment Management LLC acquired a new position in Alumis in the third quarter valued at $89,000. Wells Fargo & Company MN lifted its stake in shares of Alumis by 77.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after purchasing an additional 3,823 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Alumis during the 4th quarter worth approximately $79,000. Finally, Marshall Wace LLP acquired a new stake in Alumis in the fourth quarter worth $108,000.

Alumis Trading Down 2.5 %

ALMS stock opened at $5.08 on Wednesday. The company has a 50 day moving average of $7.38 and a two-hundred day moving average of $9.87. Alumis has a 12-month low of $4.74 and a 12-month high of $13.53.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.